Your browser doesn't support javascript.
loading
Embracing cancer complexity: Hallmarks of systemic disease.
Swanton, Charles; Bernard, Elsa; Abbosh, Chris; André, Fabrice; Auwerx, Johan; Balmain, Allan; Bar-Sagi, Dafna; Bernards, René; Bullman, Susan; DeGregori, James; Elliott, Catherine; Erez, Ayelet; Evan, Gerard; Febbraio, Mark A; Hidalgo, Andrés; Jamal-Hanjani, Mariam; Joyce, Johanna A; Kaiser, Matthew; Lamia, Katja; Locasale, Jason W; Loi, Sherene; Malanchi, Ilaria; Merad, Miriam; Musgrave, Kathryn; Patel, Ketan J; Quezada, Sergio; Wargo, Jennifer A; Weeraratna, Ashani; White, Eileen; Winkler, Frank; Wood, John N; Vousden, Karen H; Hanahan, Douglas.
Affiliation
  • Swanton C; The Francis Crick Institute, London, UK; Cancer Research UK Lung Cancer Centre of Excellence, University College London Cancer Institute, London, UK. Electronic address: charles.swanton@crick.ac.uk.
  • Bernard E; The Francis Crick Institute, London, UK; INSERM U981, Gustave Roussy, Villejuif, France.
  • Abbosh C; AstraZeneca, Cambridge, UK.
  • André F; INSERM U981, Gustave Roussy, Villejuif, France; Department of Medical Oncology, Gustave Roussy, Villejuif, France; Paris Saclay University, Kremlin-Bicetre, France.
  • Auwerx J; Laboratory of Integrative Systems Physiology, Ecole Polytechnique Federale de Lausanne, Lausanne, Switzerland.
  • Balmain A; UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA, USA.
  • Bar-Sagi D; NYU Langone Health, New York, NY, USA.
  • Bernards R; Division of Molecular Carcinogenesis, Oncode Institute, the Netherlands Cancer Institute, Amsterdam, the Netherlands.
  • Bullman S; Human Biology Division, Fred Hutchinson Cancer Center, Seattle, WA, USA.
  • DeGregori J; Department of Biochemistry and Molecular Genetics, University of Colorado Anschutz Medical Campus, Aurora, CO, USA.
  • Elliott C; Cancer Research UK, London, UK.
  • Erez A; Department of Molecular Cell Biology, Weizmann Institute of Science, Rehovot, Israel.
  • Evan G; The Francis Crick Institute, London, UK; Kings College London, London, UK.
  • Febbraio MA; Drug Discovery Biology, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, VIC, Australia.
  • Hidalgo A; Department of Immunobiology, Yale University, New Haven, CT 06519, USA; Area of Cardiovascular Regeneration, Centro Nacional de Investigaciones Cardiovasculares, 28029 Madrid, Spain.
  • Jamal-Hanjani M; Cancer Research UK Lung Cancer Centre of Excellence, University College London Cancer Institute, London, UK.
  • Joyce JA; Department of Oncology, Ludwig Institute for Cancer Research, University of Lausanne, Lausanne, Switzerland.
  • Kaiser M; Cancer Research UK, London, UK.
  • Lamia K; Department of Molecular Medicine, Scripps Research Institute, La Jolla, CA, USA.
  • Locasale JW; Department of Pharmacology and Cancer Biology, Duke University, Durham, NC, USA; Department of Molecular and Structural Biochemistry, North Carolina State University, Raleigh, NC, USA.
  • Loi S; Division of Cancer Research, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia; The Sir Department of Medical Oncology, The University of Melbourne, Parkville, VIC, Australia.
  • Malanchi I; The Francis Crick Institute, London, UK.
  • Merad M; Department of immunology and immunotherapy, Precision Immunology Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
  • Musgrave K; Translational and Clinical Research Institute, Newcastle University, Newcastle, UK; Department of Haematology, The Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, UK.
  • Patel KJ; MRC Weatherall Institute of Molecular Medicine, University of Oxford, John Radcliffe Hospital, Oxford, UK.
  • Quezada S; Cancer Immunology Unit, Research Department of Haematology, University College London Cancer Institute, London, UK.
  • Wargo JA; Department of Surgical Oncology, Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Weeraratna A; Sidney Kimmel Cancer Center, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA.
  • White E; Rutgers Cancer Institute of New Jersey, New Brunswick, NJ, USA; Ludwig Princeton Branch, Ludwig Institute for Cancer Research, Princeton, NJ, USA.
  • Winkler F; Neurology Clinic and National Center for Tumor Diseases, University Hospital Heidelberg, Heidelberg, Germany; Clinical Cooperation Unit Neuro-oncology, German Cancer Consortium (DKTK), German Cancer Research Center (DKFZ), Heidelberg, Germany.
  • Wood JN; Molecular Nociception Group, WIBR, University College London, London, UK.
  • Vousden KH; The Francis Crick Institute, London, UK. Electronic address: karen.vousden@crick.ac.uk.
  • Hanahan D; Lausanne Branch, Ludwig Institute for Cancer Research, Lausanne, Switzerland; Swiss institute for Experimental Cancer Research (ISREC), EPFL, Lausanne, Switzerland; Agora Translational Cancer Research Center, Lausanne, Switzerland. Electronic address: douglas.hanahan@epfl.ch.
Cell ; 187(7): 1589-1616, 2024 Mar 28.
Article in En | MEDLINE | ID: mdl-38552609
ABSTRACT
The last 50 years have witnessed extraordinary developments in understanding mechanisms of carcinogenesis, synthesized as the hallmarks of cancer. Despite this logical framework, our understanding of the molecular basis of systemic manifestations and the underlying causes of cancer-related death remains incomplete. Looking forward, elucidating how tumors interact with distant organs and how multifaceted environmental and physiological parameters impinge on tumors and their hosts will be crucial for advances in preventing and more effectively treating human cancers. In this perspective, we discuss complexities of cancer as a systemic disease, including tumor initiation and promotion, tumor micro- and immune macro-environments, aging, metabolism and obesity, cancer cachexia, circadian rhythms, nervous system interactions, tumor-related thrombosis, and the microbiome. Model systems incorporating human genetic variation will be essential to decipher the mechanistic basis of these phenomena and unravel gene-environment interactions, providing a modern synthesis of molecular oncology that is primed to prevent cancers and improve patient quality of life and cancer outcomes.
Subject(s)
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Neoplasms Limits: Humans Language: En Journal: Cell Year: 2024 Type: Article
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Neoplasms Limits: Humans Language: En Journal: Cell Year: 2024 Type: Article